SCHEMBL10013376

SCHEMBL10013376

CNC(=O)[C@H](CO)NC(=O)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI1 Q9ULC6 1/20 0.43
PADI4 Q9UM07 1/20 0.43
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 2/20 0.41
TSHR P16473 2/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
USP30 Q70CQ3 4/20 0.40
CHRNB2 P17787 4/20 0.40
CHRNB4 P30926 4/20 0.40
CHRNA3 P32297 4/20 0.40
CHRNA4 P43681 4/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRM1 Q13255 1/20 0.40
PSMB5 P28074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21127395 0.85 PADI1 (0.42) PADI1PADI4HDAC8HDAC6SMN1; SMN2
SCHEMBL2797000 0.81 HDAC8 (0.45) PADI1PADI4HDAC8HDAC6LMNA
SCHEMBL2795524 0.81 HDAC8 (0.45) PADI1PADI4HDAC8HDAC6LMNA
SCHEMBL2794690 0.81 HDAC8 (0.45) PADI1PADI4HDAC8HDAC6LMNA
SCHEMBL15871501 0.80 BMP1 (0.46) PADI1PADI4SMN1; SMN2MAPK1TSHR
SCHEMBL506239 0.77 NAAA (0.65) TSHRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL506240 0.77 NAAA (0.65) TSHRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL18530002 0.74 PSMB5 (0.44) PADI1PADI4HDAC8HDAC6SMN1; SMN2
SCHEMBL20485647 0.74 PSMB5 (0.44) PADI1PADI4HDAC8HDAC6SMN1; SMN2
SCHEMBL6502285 0.72 PADI1 (0.45) PADI1PADI4HDAC8HDAC6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853452-B2 Compounds, their syntheses, compositions, and methods to treat cancer THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2014-10-07 US disclosed
US-20120027844-A1 COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER XAVIER UNIVERSITY OF LOUISIANA (US) 2012-02-02 US disclosed
US-20120027844-A1 COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER XAVIER UNIVERSITY OF LOUISIANA (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027844-A1 COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER SGMS1, PHOSPHO1, MCL1 PADI1 4842/4885PADI4 4858/4885HDAC8 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.